Monopar Therapeutics(MNPR)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
MNPR Stock Analysis & AI Quality Score
Data updated 2026-07-26AI stock analysis and institutional research for Monopar Therapeutics (MNPR), a Healthcare sector company. MNPR is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of MNPR by reported 13-F value include Jupiter Topco, RA CAPITAL MANAGEMENT, L.P., BlackRock, based on the most recent SEC filings. MNPR trades on the Nasdaq exchange and files with the SEC under CIK 1645469. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate MNPR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Monopar Therapeutics directly from SEC EDGAR.
Revenue
Q2 2026
$0.00
Net Income
Q2 2026
$-5.3M
ROIC
Q2 2026
-20.3%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
Net Income
+12.0% YoYOperating Income
-3.4% YoYTotal Assets
+133.4% YoYOp. Cash Flow
-90.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | — | — | — |
| Net Income | $-13.7M +12.0% | $-15.6M -85.5% | $-8.4M +20.1% | $-10.5M -15.5% | $-9.1M -44.4% | $-6.3M |
| Operating Income | $-16.7M -3.4% | $-16.2M -83.0% | $-8.8M +16.2% | $-10.5M -15.4% | $-9.1M -40.2% | $-6.5M |
| Total Assets | $140.7M +133.4% | $60.3M +720.8% | $7.3M -44.5% | $13.2M -35.5% | $20.5M +21.7% | $16.9M |
| Operating Cash Flow | $-12.2M -90.5% | $-6.4M +18.5% | $-7.9M -8.7% | $-7.2M +1.2% | $-7.3M -56.9% | $-4.7M |
Get alerted when MNPR's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Monopar Therapeutics including:
Top Institutional Holders of MNPR
Jupiter Topco LLC
$121.7M1,312,129 shRA CAPITAL MANAGEMENT, L.P.
$61.8M667,207 shBlackRock, Inc.
$32.3M348,819 shDEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)
$30.0M323,745 shSaturn V Capital Management LP
$28.9M311,976 shSiren, L.L.C.
$25.0M270,118 shADAR1 Capital Management, LLC
$20.1M217,595 shPolar Capital Holdings Plc
$19.9M214,469 shVANGUARD CAPITAL MANAGEMENT LLC
$19.4M209,711 shADAGE CAPITAL PARTNERS GP, L.L.C.
$19.4M209,195 sh
| Fund | Value | Shares |
|---|---|---|
| Jupiter Topco LLC | $121.7M | 1,312,129 |
| RA CAPITAL MANAGEMENT, L.P. | $61.8M | 667,207 |
| BlackRock, Inc. | $32.3M | 348,819 |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | $30.0M | 323,745 |
| Saturn V Capital Management LP | $28.9M | 311,976 |
| Siren, L.L.C. | $25.0M | 270,118 |
| ADAR1 Capital Management, LLC | $20.1M | 217,595 |
| Polar Capital Holdings Plc | $19.9M | 214,469 |
| VANGUARD CAPITAL MANAGEMENT LLC | $19.4M | 209,711 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $19.4M | 209,195 |
More Healthcare Companies
View all Healthcare →Put MNPR on your watchlist
Track score changes the day Monopar Therapeutics files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is MNPR a good stock to buy?
13F Pro's AI-powered analysis of Monopar Therapeutics (MNPR) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for MNPR are available on the MNPR stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. MNPR is classified as a small company.
Which hedge funds own MNPR?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling MNPR. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Monopar Therapeutics's investment landscape.